-

Asahi Kasei Adds New Slitting Facility for SUNFORT™ to Meet Growing Demand for Advanced Semiconductor Packaging

TOKYO--(BUSINESS WIRE)--Asahi Kasei, a diversified global company, constructed a new slitting facility for SUNFORT™ dry film photoresist (DFR) at its manufacturing site in Tainan, Taiwan, on July 3. Commercial operations are scheduled to commence this month.

Asahi Kasei has been slitting SUNFORT™ DFR at its Tainan site since 1997. In recent years, demand for advanced semiconductor packaging has grown significantly, driven by AI and the resulting increase in data processing requirements. Accordingly, DFR used in semiconductor packaging must also meet increasingly stringent standards for both quality and supply reliability. In this context, Taiwan is a strategically important location with a strong concentration of semiconductor packaging-related companies, making it essential to have a supply system capable of supplying products rapidly and reliably in close proximity to customers.

Slitting is the process by which master rolls of film are cut into narrower widths in accordance with individual customer requirements. It is a critical process that directly impacts both product quality and supply reliability.

To respond to growing market demand for DFR, Asahi Kasei’s new slitting facility is equipped with state-of-the-art machines and some of the most rigorous cleanroom standards for improved productivity and dependable supply. The facility represents an investment of approximately ¥2 billion (approximately $12 million or €11 million) and will expand capacity by 40% with the potential to double current output.

SUNFORT™ DFR delivers ultra-high resolution with conventional stepper exposure systems and laser direct imaging (LDI) systems, which transfer circuit patterns onto substrates for packaging. This approach improves performance and precision in semiconductor manufacturing back-end processes.

Asahi Kasei’s investment in SUNFORT™ DFR aligns with the company’s positioning of its Electronics Business as a strategic growth driver. In May 2025, Asahi Kasei also launched SUNFORT™ TA, its newest DFR series tailored for advanced semiconductor packaging used in AI servers.

About Asahi Kasei
Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world’s challenges across its three business sectors: Healthcare, Homes, and Material. For more information, visit https://www.asahi-kasei.com/.

Contacts

Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com

Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu

Asahi Kasei

TOKYO:3407

Release Summary
Asahi Kasei has constructed a new slitting facility for SUNFORT™ dry film photoresist (DFR) at its manufacturing site in Tainan, Taiwan, on July 3.
Release Versions

Contacts

Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com

Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu

Social Media Profiles
More News From Asahi Kasei

Asahi Kasei Signs MOU With Power to Hydrogen to Accelerate Commercialization of AEM Water Electrolysis for Clean Hydrogen Production

TOKYO--(BUSINESS WIRE)--Asahi Kasei and P2H2 have signed an MOU to evaluate manufacturing scale-up and commercialization of water electrolysis systems using AEM technology....

Asahi Kasei Strengthens Carbon Footprint Transparency for Acrylonitrile Production with Independent Third-Party Verification

TOKYO--(BUSINESS WIRE)--Tongsuh Petrochemical, a subsidiary of Asahi Kasei, has obtained the “Reasonable Assurance” verification for the PCF of acrylonitrile (AN)....

Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults

TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolina, today announced that the U.S. Food and Drug Administration (FDA) has approved HOVILPRI® (pritelivir) 100 mg tablets for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacy...
Back to Newsroom